Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) Director Jason David Sawyer bought 240,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction on Wednesday, July 22nd. The shares were bought at an average price of $0.23 per share, for a total transaction of $55,200.00. Following the acquisition, the director owned 240,000 shares of the company’s stock, valued at approximately $55,200. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Greenland Mines Ltd. Common Stock Trading Up 3.2%
Greenland Mines Ltd. Common Stock stock opened at $0.20 on Friday. The firm has a market capitalization of $27.09 million, a P/E ratio of -0.61 and a beta of 7.05. The business has a 50-day moving average of $0.27 and a 200-day moving average of $0.37. Greenland Mines Ltd. Common Stock has a 1 year low of $0.16 and a 1 year high of $1.04.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last released its quarterly earnings data on Wednesday, May 20th. The company reported ($0.15) earnings per share for the quarter.
Institutional Trading of Greenland Mines Ltd. Common Stock
Analysts Set New Price Targets
A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings upgraded Greenland Mines Ltd. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Greenland Mines Ltd. Common Stock has an average rating of “Sell”.
Read Our Latest Analysis on Greenland Mines Ltd. Common Stock
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
